Insights
Independent analysis of company developments, industry trends, and capital markets, with a focus on undercovered public companies. We examine what changed, why it matters, and the implications for investors.
Topics
88 insights
Mining & Critical MineralsIvanhoe’s Copper Recovery Gains Support From Acid Sales and Solar Power
Kamoa-Kakula’s latest operating update shows how local acid demand and a changing power supply can influence copper margins. Understanding the benefit requires following the project from underground ore through processing, sales and the costs of its continuing recovery.
Special SituationsExail’s Thales Takeover Brings Its Earlier Acquisition Financing Back Into Focus
Exail’s revised accounts bring obligations from its 2022 expansion into focus as Thales pursues a €134-per-share takeover. Its maritime robotics and navigation businesses are growing, while settlement rights held by ICG and employees add complexity to the acquisition’s financial structure.
Mining & Critical MineralsCaledonia’s Lower Gold Guidance Still Requires a Sharp Fourth-Quarter Recovery at Blanket
Caledonia has reduced its 2026 production outlook and raised unit-cost guidance after equipment and processing problems at Blanket. The revised target still assumes a fourth-quarter recovery, while deferred capital expenditure provides near-term cash relief without reducing the underlying investment requirement.
Biotechnology & HealthcareViatris’s Pacira Deal Buys Established Pain Medicines, but Growth Must Justify the Price
Viatris’s $1.65 billion cash offer adds two marketed non-opioid pain medicines and a U.S. commercial platform. The investment case depends on product durability, international expansion and cash returns, with Pacira’s debt, recent divestiture and adjusted earnings complicating a simple acquisition-multiple comparison.
Technology & SemiconductorsWolfspeed’s $1.5 Billion Government Loan Comes With a $750 Million Capital Test
The conditional 30-year facility could replace high-cost first-lien debt and fund U.S. silicon carbide and gallium nitride capacity. Yet no loan has closed, later draws require commercial milestones, and Wolfspeed must provide at least $750 million of qualifying capital while issuing warrants.
Technology & SemiconductorsXanadu’s GlobalFoundries Partnership Moves Quantum Computing Toward Manufacturing, With Economics Still Unproven
A 300 mm foundry partnership addresses the production of photonic chips and detectors needed for Xanadu’s planned quantum systems. The investment case now depends on translating component performance into manufacturing yields, integrated demonstrators and commercially useful machines while controlling development spending.
EnergyEnergy Transfer’s $2.6 Billion Vaquero Deal Buys Volumes for Its Wider Network
The acquisition adds contracted Delaware Basin gas-processing capacity already connected to Energy Transfer’s downstream infrastructure. Returns will depend on capturing additional transportation and export fees while funding a cash-heavy purchase alongside an expanding construction program.
Biotechnology & HealthcareVaxcyte’s Phase 3 Success Advances a Broader Vaccine Toward Its Next Regulatory Tests
VAX-31 passed every primary endpoint in its pivotal adult trial, supporting a broader pneumococcal vaccine profile. Individual comparator results, remaining manufacturing studies and rising development spending will shape the path to Vaxcyte’s planned 2028 filing and eventual commercial opportunity.
Capital Markets & M&ASchneider’s $23.7 Billion PTC Deal Needs More Than Cost Savings
Schneider Electric is paying a 42.3% premium for PTC and funding most of the purchase with debt. The advertised valuation falls from 21 times to 13 times 2027 adjusted EBITA only after a demanding combination of cost savings and commercial synergies.
Biotechnology & HealthcareJaypirca Moves Into First-Line CLL, Expanding Lilly’s Oncology Opportunity in a Crowded Market
FDA approval brings Lilly’s noncovalent BTK inhibitor into initial treatment for eligible patients with chronic lymphocytic leukemia. The commercial opportunity now extends earlier in the disease course, while competing targeted therapies, treatment duration and tolerability will determine how much of that opportunity becomes revenue.
Capital Markets & M&AFlowco’s $113 Million Deal Expands Its Role in Keeping Older Wells Productive
Flowco’s acquisition of Lifting Solutions adds continuous rod and progressing cavity pumps to its artificial lift portfolio. The purchase extends its Canadian and international reach, with returns dependent on equipment performance, cross-selling and cash generation as the group absorbs a second acquisition this year.
Technology & SemiconductorsMicron’s Customers Are Helping Fund Its Next Expansion as Memory Demand Surges
Customer deposits exceeded Micron’s quarterly net capital expenditure as revenue and operating cash flow reached new highs. Combined with longer-term purchase agreements, that funding gives Micron greater capacity to expand supply, while shifting the investment debate toward contract profitability and returns on new factories.